New modalities for non-invasive positive pressure ventilation: A review article

Abstract
Efficiency of non-invasive positive pressure ventilation in the treatment of respiratory failure has been shown in many published studies. In this review article, we introduced new modalities of non-invasive ventilation (NIV), clinical settings in which NIV can be used and a practical summary of the latest official guidelines published by the European Respiratory Clinical Practice. Clinical trials and review articles in four databases up to 25 February 2018 about new modalities of non-invasive positive pressure ventilation were reviewed. Commonly used modalities for treatment of respiratory failure include: CPAP (continuous positive airway pressure) and BiPAP (bilevel positive airway pressure) or NIPSV (noninvasive pressure support ventilation). The limitations of the BiPAP method are the trigger and cycle asynchrony, inadequate volume delivery and increased respiratory rate. Newer methods, such as adaptive servo-ventilation, have been developed to treat central and complex sleep apnea and the NAVA (neutrally adjusted ventilatory assist) to improve the trigger and cycle asynchrony.

In the proportional assist ventilation, unlike the pressure support ventilation, with increased patient effort (flow) the tidal volume increases and it prevents the increase in the respiratory rate and respiratory distress. High-flow nasal cannula is a non-invasive technique that does not provide respiratory support, but provides a mixture of oxygen to the patient. The use of non-invasive pursed-lip breathing ventilation in chronic obstructive pulmonary disease (COPD) patients reduces dyspnea (decreases respiratory rate) and increases blood oxygen saturation. New modalities of NIV improve patient comfort and patient–ventilator interactions, and are recommended in patients with respiratory failure.

Keywords: Non-invasive ventilation, adaptive servo-ventilation, acute respiratory failure

Citation:
Seyfi S, Amri P, Mouodi S. New modalities for non-invasive positive pressure ventilation: A review article. Caspian J Intern Med 2019; 10(1): 1-6.

The main cause of the mechanical ventilation is acute respiratory failure (1). Mechanical ventilation is performed in two ways, invasive and non-invasive ventilation. The mechanical ventilation of the lungs using mask is called non-invasive positive pressure ventilation (NIPPV) (2, 3). Evidence suggests that non-invasive ventilation compared to invasive positive pressure ventilation (IPPV) decreases the risk of ventilator associated pneumonia (VAP), sinusitis, sepsis, and ultimately reduces the rate of hospitalization and mortality (4). The present study aimed to represent the new modalities for non-invasive positive pressure ventilation and their clinical indications.

Methods

Data sources and search criteria: We searched clinical trials and review articles in four databases (Pubmed, the Cochrane Database of Systematic Reviews, Scopus and Magiran) up to February 25, 2018.
At first, all clinical trials, systematic reviews and review articles which used the entry terms "positive end-expiratory pressure" OR "positive-pressure ventilation" OR "positive-pressure respiration" in title, abstract or keywords were included. Subsequently, the manuscripts that mentioned non-invasive positive pressure ventilation and emphasized on new modalities of this procedure were selected. We also reviewed the reference lists of included studies to identify review articles related to search criteria. As well, we only searched Persian and English language published manuscripts. Two reviewers updated the abstract search. Ethics committee approval was not required for this review article.

**Study selection:** We included clinical trials and review articles that reported indications and advantages of new modalities of NIPPV.

**Data extraction and quality assessment:** Two authors, unblinded to data sources, summarized the included studies. Quality assessment was performed with emphasis on reporting a new modality on application of NIPPV and outcome reporting.

**Discussion**

We included 16 clinical trials, review articles or systematic reviews which used the mentioned keywords in the title, abstract or keywords and emphasized on NIPPV new modalities and their clinical indications.

**Indications for non-invasive ventilation:** Non-invasive ventilation indications are extensively increasing. One of the common indications of NIPPV is the COPD treatment, as well as the weaning of these patients from invasive ventilation (5, 6).

Other non-invasive ventilation indications include: Asthma, upper airway obstruction, mild to moderate hypoxemia, central apnea or hypoventilation syndrome (Table 1). The exclusion criteria for NIPPV included: Immediate cardiac arrest, hemodynamic instability, shock, life threatening cardiac ischemia, dangerous arrhythmias, patients who do not cooperate, increased discharge and airway surgery.

In cases of acute and short-term diseases, an oronasal mask, and in chronic and prolonged cases, a nasal mask should be used; and if the patient does not cooperate well, full face masks are recommended (4, 6, 7, 9). In NIPPV, all ventilation techniques are applicable, but CPAP (continuous positive airway pressure) and BiPAP (bilevel positive airway pressure) or NIPSV (noninvasive pressure support ventilation) + PEEP (positive end-expiratory pressure) are the most commonly used methods (4, 6, 7, 9).

**Table 1. Indications for non-invasive positive pressure ventilation (6-8)**

| Strong evidence (Level A) | Reasonable evidence (Level B) |
|---------------------------|-------------------------------|
| Acute exacerbations of COPD | Acute cardiogenic pulmonary edema (use of CPAP) |
| To facilitate weaning in COPD | Immunocompromised patients |
| Acute cardiogenic pulmonary edema (use of CPAP) | Postoperative respiratory failure |
| Immunocompromised patients | Asthma |
| Postoperative respiratory failure | Not intubating patients |
| Asthma | Obstructive sleep apnea or obesity hypoventilation |
| Not intubating patients | Cohort series, case reports (Level C) |
| Obstructive sleep apnea or obesity hypoventilation | During bronchoscopy |
| Cohort series, case reports (Level C) | Cystic fibrosis |
| During bronchoscopy | Restrictive disorders |
| Cystic fibrosis | Upper airway obstruction |
| Restrictive disorders | Acute respiratory distress syndrome |

COPD: chronic obstructive pulmonary disease  
CPAP: continuous positive airway pressure

**NIPPV setting:** CPAP is used in patients with acute congestive heart failure and obstructive sleep apnea (OSA). In patients with obstructive sleep apnea, the CPAP is adjusted between 5 to 12 centimeters of water during sleep, after attaching the mask.

BiPAP is the most commonly used mode in noninvasive method. In patients with COPD and other patients, after attaching the mask on the patient's face, the setting will be 3-5 cm of water expiratory positive airway pressure (EPAP) and 5-15 cm of water inspiratory positive airway pressure (IPAP).

EPAP is initially set on lower number, and like PEEP in case of hypoxemia, it can be set on the maximum of 10-12 cm/H2O.

If the patient has hypercarbia or tachypnea, the IPAP increases to a maximum of 20-25cm/H2O. The difference between the designated IPAP and the EPAP (figure 1) is called PS (5, 8-14)
Blood pressure, heart rate, respiratory rate, Paco2, PH and PaO2 should be monitored during NIPPV. When non-invasive ventilation is effective, the above mentioned variables tend to be normal. The application rate of NIPPV depends on the severity of the underlying disease and the patient's admission and varies from one hour to 23 hours a day (4, 6, 9). The limitations of the CPAP method include the complications related to the mask situation on the face such as wound and necrosis of the nasal bridge resulted in patients’ speaking and eating (4, 6, 9). The limitations of the BiPAP procedure include the complications of mask intolerance, eye damage, eating and talking and phlegm disorder, patient-ventilator asynchrony including trigger and cycle asynchrony (15).

**PAV (Proportional assist ventilation):** This PSV-like mode is a spontaneous breathing support mode. In fact, it is pressure controlled, patient triggered, pressure limited and flow cycled; however, in the case of hypercarbia, the ventilator feels the patient's increased sensitivity to the inhale flow, and, in contrast to the PS, it increases the current volume instead of increasing the number of respiration; therefore, it imitates the natural respiration pattern which COPD patients can tolerate much better. In this mode, operator sets the percentage of the assistance for the current volume, the percentage of flow assistance (based on resistance and elastance). PEEP and FIO2 should be adjusted. In this mode, the risk of Auto-PEEP and the disproportionate support level will be reduced (6, 16, 17).

This mode is indicated in patients who had asynchrony with NIPSV. The advantages of this mode include better compatibility than NIPSV and prevention of over-assistance (18).

**Adaptive servo ventilation (ASV):** A large proportion of patients with chronic heart failure may have chyne stoke respiration. In addition, some of them have coincidently OSA and CSA. An increase in CO2 can exacerbate heart failure. In these cases, CPAP alone cannot help. In the ASV mode, which was initially used to treat central apnea, it is possible to prevent obstructive apnea by regulating exhaust-pressure during expiration. In this mode, the inspiratory pressure and PEEP are changing based on the patient's respiratory pattern. The use of ASV can be dangerous in CHF patients with sleep disorders and low EF (17-20).

**NAVA (Neurally adjusted ventilator assist):** In the NAVA, the ventilator detects the contraction signal of the aperture by the EMG electrode located in the lower esophagus, and controls the ventilator, flow, volume and pressure without delay. Unlike the PAV, the patient's respiratory center controls all auxiliary breathing process from the trigger to the end of the inspiratory cycle. Currently, this mode has the highest degree of coordination in starting ventilation and maximum compatibility with the patient’s inspiration. Its limitation includes the necessity for esophageal catheter device (7, 18, 21, 22).

**AVAPS (Average volume assured pressure support) ventilation:** AVAPS is one of the intelligent ventilation modes that delivers the preset volume securely by changing the pressure support level. Studies have not shown the superiority of this mode in comparison with NIV in the conventional way. Its limitation includes increased inspiratory pressure in cases of low lung compliance. Its main indication was observed in COPD patients and hypoventilation syndrome (18, 23, 24).

**HFNC (High flow nasal cannula):** HFNC is a new method for oxygen therapy that provides warm and humid oxygen to patients with special tools using the flow up to 60 liters per minute with FIO2=21- 100% (9, 25, 26). HFNC creates a low level of PEEP, reduces airway resistance, and washouts air chips. The benefits of HFNC are the lack of a ventilator, good compliance with the patient, and improve oxygenation. Its main disadvantage is the lack of ventilation support. The main indications of its application are hypoxemic respiratory failure, acute heart failure requiring a long NIV, and mechanical ventilation weaning (18). Treatment of
underlying diseases and oxygen are the basis of the AHRF treatment. Oxygen is prescribed in nasal cannulas, or face mask, NIV, and MV.

The conventional oxygen rate given by the face mask or nasal cannula methods is the maximum of 15 liters per minute, which is not enough to provide oxygen for the hypoxic patient (27).

Yue-nan et al. compared the effects of HFNC with humid oxygen and NIPPV in the treatment of acute respiratory failure in a review article. Eighteen papers and 3881 patients were examined for ICU tracheal intubation and mortality. There was no significant difference between HFNC and NIPPV; however, the amount of intubation was lower comparing to conventional HFNC oxygen therapy. In terms of mortality and duration of hospitalization in ICU, HFNC showed no superiority on conventional oxygen therapy and NIPPV (27, 28). Okuda et al. examined the effect of HFNC on the parameters of respiratory physiological parameters through esophageal balloon in 10 patients, with off, 30 L / min and 50 L / min methods. The volume of flow and PEEP increased with increased flow and decreased respiratory rate (20, 29).

**PLB (Pursed lips ventilation):** PLB is a strategy in which the air exits slowly and is controlled by puckered lips during exhalation. PLB has indication for COPD patients who have dyspnea. PLB improves ventilation, slows retention of air, prolongs airway opening, reduces respiratory rate, reduces respiratory rate, outflows of old air and brings the new air flow to the lungs. In this method, the patient sits on the chair, relaxes the shoulder and neck muscles; then slowly inhales with the nose for 2 seconds, and exhales slowly with puckered lips within 4 seconds (30, 31).

**NIHFV (Non-invasive high-frequency ventilation):** NIHFV is a relatively new mode which is more commonly used in non-invasive ventilation for infants. In this mode, the flow is less than the anatomical dead space (2ml / kg) with high respiration rate (80- 1600 per minute or 3-10 Hz) and mean airway pressure (MAP) (29, 32).

**Recommendations for using NIV for the treatment of acute respiratory failure based on the official ERS / ATS clinical practice guidelines:** (4, 7, 9)

- Bi-level NIV is a selective method in treatment of COPD exacerbation as well as preventing intubation in these patients.
- Bi-level NIV or CPAP is recommended in patients with cardiogenic pulmonary edema.
- There is insufficient evidence to suggest the use of NIV in asthmatic patients.
- Early NIV is recommended for the treatment of acute respiratory failure in immunocompromised patients.
- There is insufficient evidence to suggest the use of NIV in patients with NOVO ARF.
- NIV is recommended for post-operative ARF.
- NIV is suggested for end stage cancer patients with dyspnea.
- NIV is recommended for the treatment of acute respiratory failure after chest trauma.
- There is insufficient evidence to suggest using NIV in patients with pandemic viruses.
- NIV is recommended for prevention of respiratory failure after extubation in high risk patients. This method should not be used in the treatment of respiratory distress after extubation.
- NIV is recommended for the isolation of ventilators in patients with hypercapnic respiratory failure, but there is not enough evidence to support the treatment of hypoxic respiratory failure.

The advantage of our study is to describe the indications and clinical aspects of the most important new modalities of NIPPV. A few clinical trials or review articles have been concerned on technical approaches of all new modalities of NIPPV, in recent years. Some studies described a number of these modalities according to target patients; for example, Masip described the indications and clinical considerations of CPAP and NIPSV in acute heart failure patients (22). Elgebaly compared intermittent positive pressure ventilation (IPPV) and NIPPV in the management of acute respiratory failure and hemodynamic parameters after open-heart surgery (15) and Ferreira evaluated NAVA and PSV in critically ill patients (24).

In our study, we described all these new modalities which can be used in the conditions which sufficient human resources and equipment are not available, especially in developing countries.

It is recommended for future researches to design and perform randomized clinical trials to compare the impacts of all of these new modalities in the different aspects of patients’ treatment. Furthermore, the implementation of a new modality of NIPPV –as an intelligent system- which can trigger the patient’s respiration depending on end-tidal carbon dioxide concentration and regulate the respiratory rate, automatically is suggested.
Acknowledgments

Hereby, the significant cooperation of Ms. Damavandi and Ms. Heidarnia in treatment and nursing processes is highly appreciated, and so is the Clinical Research Development Unit of Ayatollah Rouhani Hospital, Babol University of Medical Sciences for editing this article.

Funding: No funding was received.
Conflict of Interest: None declared.

References
1. Gadre SK, Duggal A, Mireles-Cabodevila E, et al. Acute respiratory failure requiring mechanical ventilation in severe chronic obstructive pulmonary disease (COPD). Medicine (Baltimore) 2018; 97: e0487.
2. Kock KS, Maurici R. Respiratory mechanics, ventilator-associated pneumonia and outcomes in intensive care unit. World J Crit Care Med 2018; 7: 24-30.
3. Ambrosino N, Vitacca M. The patient needing prolonged mechanical ventilation: a narrative review. Multidiscip Resp Med 2018; 13: 6.
4. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J 2017; 50: pii: 1602426.
5. Lindenauer PK, Stefan MS, Shieh MS, et al. Outcomes associated with invasive and noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease. JAMA Intern Med 2014; 174: 1982-93.
6. Vilaca M, Aragao I, Cardoso T, Dias C, Cabral-Campello G. The Role of Noninvasive Ventilation in Patients with “Do Not Intubate” Order in the Emergency Setting. PLoS One 2016; 11: e0149649.
7. Simonds AK, Hare A. New modalities for non-invasive ventilation. Clin Med 2013; 13: s41-5.
8. Vital FM, Saconato H, Ladeira MT, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev 2008; 3: CD005351.
9. Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 49: pii: 1600791.
10. Zhang J, Wang Y, Cao J, Chen B, Feng J. Noninvasive ventilation with complex critical care ventilator in the treatment of acute exacerbation of chronic obstructive pulmonary disease. J Int Med Res 2014; 42: 1102-9.
11. Goodacre S, Stevens JW, Pandor A, et al. Prehospital noninvasive ventilation for acute respiratory failure: systematic review, network meta-analysis, and individual patient data meta-analysis. Acad Emerg Med 2014; 21: 960-70.
12. Mas A, Masip J. Noninvasive ventilation in acute respiratory failure. Int J Chron Obstruct Pulmon Dis 2014; 9: 837-52.
13. Ozsancak Ugurlu A, Sidhom SS, Khodabandeh A, et al. Use and outcomes of noninvasive positive pressure ventilation in acute care hospitals in Massachusetts. Chest 2014; 145: 964-71.
14. Elgebaly AS. Does bilevel positive airway pressure improve outcome of acute respiratory failure after open-heart surgery? Ann Card Anaesth 2017; 20: 416-21.
15. Jean-Pierre F, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxic respiratory failure. N Engl J Med 2015; 372: 2185-96.
16. Gautam1 PL, Kaur G, Katyal S, Gupta R, Sandhu P, Gautam N. Comparison of patient-ventilator asynchrony during pressure support ventilation and proportional assist ventilation modes in surgical Intensive Care Unit: A randomized crossover study. Indian J Crit Care Med 2016; 20: 689-94.
17. Vasconcelos RS, Sales RP, Melo LHP, et al. Influences of duration of inspiratory effort, respiratory mechanics, and ventilator type on asynchrony with pressure support and proportional assist ventilation. Respir Care 2017; 62: 550-7.
18. Masip J, Peacock WF, Price S, et al. Indications and practical approach to non-invasive ventilation in acute heart failure. Eur Heart J 2018; 39: 17-25.
19. Tong S, Gower J, Morgan A, Gadbois K, Wisbach G. Noninvasive positive pressure ventilation in the immediate post–bariatric surgery care of patients with obstructive sleep apnea: a systematic review. Surg Obes Relat Dis 2017; 13: 1227-33.
20. Ramalho SHR, Shah AM. Central sleep apnoea in heart failure with reduced ejection fraction, adaptive servo-ventilation, and left ventricular ejection fraction: the (still) missing link. Eur J Heart Fail 2018; 20: 545-7.
21. Ferreira JC, Diniz-Silva F, Moriya HT, et al. Neurally Adjusted Ventilatory Assist (NAVA) or Pressure Support Ventilation (PSV) during spontaneous breathing trials in critically ill patients: a crossover trial. BMC Pulm Med 2017; 17: 139.

22. Longhini F, Pan C, Xie J, et al. New setting of neurally adjusted ventilatory assist for noninvasive ventilation by facial mask: a physiologic study. Crit Care 2017; 21: 170.

23. Çiftci F, Çiledağ A, Erol S, et al. Evaluation of the feasibility of average volume-assured pressure support ventilation in the treatment of acute hypercapnic respiratory failure associated with chronic obstructive pulmonary disease: A pilot study. J Crit Care 2017; 39: 232-7.

24. Gentin N, Williamson B, Thambipillay G, Teng A. Nocturnal respiratory failure in a child with congenital myopathy—management using average volume-assured pressure support (AVAPS). Respirol Case Rep 2015; 3: 115-7.

25. Hernández G, Vaquero C, González P, et al. Effect of postextubation high-flow nasal cannula vs conventional oxygen therapy on reintubation in low-risk patients: a randomized clinical trial. JAMA 2016; 315: 1354-61.

26. Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. Chest 2015; 148: 253-61.

27. Ni YN, Luo J, Yu H, et al. Can high-flow nasal cannula reduce the rate of reintubation in adult patients after extubation? A meta-analysis. BMC Pulm Med 2017; 17: 142.

28. Ni YN, Wang T, Yu H, Liang BM, Liang ZA. The effect of sedation and/or analgesia as rescue treatment during noninvasive positive pressure ventilation in the patients with Interface intolerance after Extubation. BMC Pulm Med 2017; 17: 125.

29. Mukerji A, Sarmiento K, Lee B, Hassall K, Shah V. Non-invasive high-frequency ventilation versus bi-phasic continuous positive airway pressure (BP-CPAP) following CPAP failure in infants< 1250 g: a pilot randomized controlled trial. J Perinatol 2017; 37: 49-53.

30. Mayer AF, Karloh M, Dos Santos K, de Araujo CLP, Gulart AA. Effects of acute use of pursed-lips breathing during exercise in patients with COPD: a systematic review and meta-analysis. Physiotherapy 2018; 104: 9-17.

31. Cabral LF, D'Elia TC, Marins DS, Zin WA, Guimarães FS. Pursed lip breathing improves exercise tolerance in COPD: a randomized crossover study. Eur J Phys Rehabil Med 2015; 51: 79-88.

32. Fischer HS, Rimensberger PC. Early noninvasive high-frequency oscillatory ventilation in the primary treatment of respiratory distress syndrome. Pediatr Pulmonol 2018; 53: 126-7.